- Home
- ASIX vs BCAX Comparison
ASIX vs BCAX Comparison
Compare ASIX & BCAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASIX
- BCAX
- Stock Information
- Founded
- ASIX 2016
- BCAX 2018
- Country
- ASIX United States
- BCAX United States
- Employees
- ASIX N/A
- BCAX N/A
- Industry
- ASIX Major Chemicals
- BCAX
- Sector
- ASIX Industrials
- BCAX
- Exchange
- ASIX Nasdaq
- BCAX NYSE
- Market Cap
- ASIX 663.1M
- BCAX 670.9M
- IPO Year
- ASIX N/A
- BCAX 2024
- Fundamental
- Price
- ASIX $23.26
- BCAX $13.13
- Analyst Decision
- ASIX Hold
- BCAX Buy
- Analyst Count
- ASIX 1
- BCAX 7
- Target Price
- ASIX $26.00
- BCAX $29.67
- AVG Volume (30 Days)
- ASIX 225.8K
- BCAX 567.2K
- Earning Date
- ASIX 05-02-2025
- BCAX 05-20-2025
- Dividend Yield
- ASIX 2.80%
- BCAX N/A
- EPS Growth
- ASIX 3682.26
- BCAX N/A
- EPS
- ASIX 3.11
- BCAX N/A
- Revenue
- ASIX $1,558,519,000.00
- BCAX N/A
- Revenue This Year
- ASIX $5.43
- BCAX N/A
- Revenue Next Year
- ASIX $5.44
- BCAX N/A
- P/E Ratio
- ASIX $7.32
- BCAX N/A
- Revenue Growth
- ASIX 6.03
- BCAX N/A
- 52 Week Low
- ASIX $18.44
- BCAX $8.91
- 52 Week High
- ASIX $33.00
- BCAX $28.09
- Technical
- Relative Strength Index (RSI)
- ASIX 61.98
- BCAX N/A
- Support Level
- ASIX $21.91
- BCAX N/A
- Resistance Level
- ASIX $24.31
- BCAX N/A
- Average True Range (ATR)
- ASIX 0.88
- BCAX 0.00
- MACD
- ASIX 0.43
- BCAX 0.00
- Stochastic Oscillator
- ASIX 77.88
- BCAX 0.00
About ASIX AdvanSix Inc.
AdvanSix Inc. is a diversified chemistry company playing a critical role in globally supply chains, innovating and delivering essential products for customers in a wide variety of end markets and applications that touch people's lives, such as building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives and electronics. The company key products includes: Nylon, Caprolactam, Plant Nutrients, and Chemical Intermediates The majority of sales is from Plant Nutrients products.
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.